NEWYou now have the option to listen to news articles!
During a recent interview, Food and Drug Administration Commissioner Marty Makary stated that he currently has no predetermined plans to make any changes to the policies regarding the abortion pill mifepristone, which is specifically designed for ending pregnancies within the first 10 weeks.
Makary mentioned in an interview with POLITICO, “We are continuously reviewing safety data on mifepristone, as required by previous administrations. It is important to keep an open mind, listen to different perspectives, and make decisions based on what is believed to be the right course of action.”
These statements align with those made by Makary during the Semafor World Economy Summit in April.
At the summit, Makary emphasized that there are no immediate plans to restrict access to the abortion pill, but emphasized that the FDA would not hesitate to take action if safety concerns were identified based on data.
ABORTION PILL MIFEPRISTONE SPARKS NEW PRO-LIFE DEBATE AS SOME DOCTORS STRESS SAFETY CONCERNS
Boxes of the drug mifepristone sit on a shelf at the West Alabama Women’s Center in Tuscaloosa, Ala., on March 16, 2022. On Tuesday, March 26, 2024, the U.S. Supreme Court will take up a case that could impact how women get access to mifepristone, one of the two pills used in the most common type of abortion in the nation.
Makary further stated, “Ongoing data related to mifepristone is being examined by the FDA. Therefore, if the data reveals any significant concerns, we cannot guarantee that action will not be taken.”
Senator Josh Hawley of Missouri expressed safety worries regarding mifepristone in a letter to Makary dated April 28.
SENATOR INTRODUCES LEGISLATION TO REIN IN WIDELY USED, CONTROVERSIAL ABORTION PILL
Dr. Makary is a cancer surgeon, researcher at Johns Hopkins University, and has also been a Fox News commentator. (Getty Images)
Hawley urged Makary to carefully consider the new data and take necessary steps to ensure the safety of American women when using mifepristone.
CLICK HERE TO GET THE FOX NEWS APP
Mifepristone (Mifeprex) and Misoprostol, the two drugs used in a medication abortion, are seen at the Women’s Reproductive Clinic, which provides legal medication abortion services, in Santa Teresa, New Mexico, on June 17, 2022. (ROBYN BECK/AFP via Getty Images)
Makary reiterated during the POLITICO interview that there are no immediate plans to alter the policies related to mifepristone, but he remains open to feedback and concerns from various sources.
The FDA and Senator Hawley were both contacted by Fox News Digital for further comments.
